JP2018512401A5 - - Google Patents

Download PDF

Info

Publication number
JP2018512401A5
JP2018512401A5 JP2017548089A JP2017548089A JP2018512401A5 JP 2018512401 A5 JP2018512401 A5 JP 2018512401A5 JP 2017548089 A JP2017548089 A JP 2017548089A JP 2017548089 A JP2017548089 A JP 2017548089A JP 2018512401 A5 JP2018512401 A5 JP 2018512401A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
tumor
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017548089A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512401A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/021843 external-priority patent/WO2016145234A2/en
Publication of JP2018512401A publication Critical patent/JP2018512401A/ja
Publication of JP2018512401A5 publication Critical patent/JP2018512401A5/ja
Pending legal-status Critical Current

Links

JP2017548089A 2015-03-12 2016-03-10 Ｍｋ２阻害剤ペプチド含有組成物を用いた非小細胞肺癌の治療を目的とするその使用 Pending JP2018512401A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562132374P 2015-03-12 2015-03-12
US62/132,374 2015-03-12
PCT/US2016/021843 WO2016145234A2 (en) 2015-03-12 2016-03-10 Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same

Publications (2)

Publication Number Publication Date
JP2018512401A JP2018512401A (ja) 2018-05-17
JP2018512401A5 true JP2018512401A5 (enExample) 2019-04-25

Family

ID=56880599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017548089A Pending JP2018512401A (ja) 2015-03-12 2016-03-10 Ｍｋ２阻害剤ペプチド含有組成物を用いた非小細胞肺癌の治療を目的とするその使用

Country Status (13)

Country Link
US (1) US9999655B2 (enExample)
EP (1) EP3268022A4 (enExample)
JP (1) JP2018512401A (enExample)
KR (1) KR20170125090A (enExample)
CN (1) CN107921082A (enExample)
AU (1) AU2016229017A1 (enExample)
BR (1) BR112017019343A2 (enExample)
CA (1) CA2978941A1 (enExample)
HK (1) HK1249433A1 (enExample)
MX (1) MX2017011633A (enExample)
RU (1) RU2017135072A (enExample)
SG (1) SG11201707281QA (enExample)
WO (1) WO2016145234A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102827A1 (en) * 2016-12-04 2018-06-07 Expression Pathology, Inc. Improved methods of treating lung cancer by predicting responders to cisplatin-pemetrexed combination therapy
CN110662844A (zh) * 2017-05-22 2020-01-07 内盖夫生物技术国家研究所有限公司 用于肺癌的诊断的生物标志物
US10952799B2 (en) * 2017-05-31 2021-03-23 Covidien Lp Systems and methods for navigational bronchoscopy and selective drug delivery
WO2018231722A1 (en) * 2017-06-12 2018-12-20 Moerae Matrix, Inc. Immunomodulatory effect of inhaled kinase inhibitor peptides in lung
CA3102328A1 (en) * 2018-06-12 2019-12-19 Universite De Geneve Peptidic protein kinase c inhibitors and uses thereof
WO2020102670A1 (en) * 2018-11-15 2020-05-22 Nantomics, Llc Classification based on characterization analysis methods and systems
EP4004548B1 (en) 2019-07-29 2026-01-14 Yeda Research and Development Co. Ltd Methods of treating and diagnosing lung cancer
CN113261532A (zh) * 2020-02-17 2021-08-17 中山大学 一种肺癌动物模型的构建方法
WO2021178449A1 (en) * 2020-03-02 2021-09-10 Washington University Compositions and methods for the treatment of pancreatic cancer
CA3197627A1 (en) * 2020-11-18 2022-05-27 Kimberly SHEPARD Inhalable dry powder formulations comprising angiogenesis inhibitors
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
US12668598B2 (en) 2022-10-27 2026-06-30 Bristol-Myers Squibb Company MK2 inhibitors and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
DK172541B1 (da) 1982-10-08 1998-12-07 Glaxo Group Ltd Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
AU4115693A (en) 1992-04-24 1993-11-29 Sri International In vivo homologous sequence targeting in eukaryotic cells
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DK0733059T3 (da) 1993-12-09 2000-10-16 Univ Jefferson Forbindelser og fremgangsmåder til site-rettede mutationer i eukaryote celler
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
DK1165050T3 (da) 1999-04-05 2006-05-01 Mannkind Corp Fremgangsmåde til dannelse af fint pulver
ES2395096T3 (es) 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20060039985A1 (en) 2004-04-27 2006-02-23 Bennett David B Methotrexate compositions
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
BRPI0514410A (pt) 2004-08-23 2008-06-10 Mannkind Corp fornecimento pulmonar de inibidores de fosfodiesterase do tipo 5
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
ES2594281T3 (es) 2007-01-10 2016-12-19 Purdue Research Foundation Inhibidores polipeptídicos de HSP27 quinasa y usos de los mismos
DK2185698T3 (en) * 2007-08-07 2015-07-27 Purdue Research Foundation Kinase Inhibitors and Uses thereof
CN102256613B (zh) 2008-10-20 2014-09-10 莫伊莱麦屈克斯公司 用于治疗或者预防粘连的多肽
US9327008B2 (en) 2008-12-10 2016-05-03 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US9890195B2 (en) 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
EP2575855A4 (en) 2010-05-24 2014-03-12 Moerae Matrix Inc METHOD FOR TREATING OR PREVENTING VASCULAR GRAFT BREAKAGE
US10105356B2 (en) * 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CN108014340A (zh) * 2011-04-12 2018-05-11 莫伊莱麦屈克斯公司 用于预防或治疗以成纤维细胞异常增殖及细胞外基质沉积为特征的疾病的组合物和方法
US9890200B2 (en) * 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
EP3467124A1 (en) * 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
US20140072613A1 (en) 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring

Similar Documents

Publication Publication Date Title
RU2017135072A (ru) Применение пептидсодержащих композиций ингибитора mk2 для лечения немелкоклеточного рака легкого
JP6685875B2 (ja) 治療薬の組み合わせおよび投与の様式ならびに併用療法
TWI599369B (zh) 包含阿柏西普（ａｆｌｉｂｅｒｃｅｐｔ）、醛葉酸、５－氟尿嘧啶（５－ｆｕ）及伊立替康（ｉｒｉｎｏｔｅｃａｎ）（ｆｏｌｆｉｒｉ）之組合物
Zarogoulidis et al. Feasibility and effectiveness of inhaled carboplatin in NSCLC patients
Wauthoz et al. Inhaled cytotoxic chemotherapy: Clinical challenges, recent developments, and future prospects
JP2022031331A (ja) 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法
Fulzele et al. Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model
Paudel et al. Targeting lung cancer using advanced drug delivery systems
Chen et al. Nab-paclitaxel (abraxane)-based chemotherapy to treat elderly patients with advanced non-small-cell lung cancer: a single center, randomized and open-label clinical trial
Lee et al. Paclitaxel-loaded polymeric micelle (230 mg/m2) and cisplatin (60 mg/m2) vs. paclitaxel (175 mg/m2) and cisplatin (60 mg/m2) in advanced Non–small-cell lung cancer: a multicenter randomized phase IIB trial
Kentepozidis et al. Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group
Shih et al. Bozitinib, a highly selective inhibitor of cMet, demonstrates robust activity in gastric, lung, hepatic and pancreatic in vivo models
Wysocka et al. Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma
TW202245768A (zh) 用於治療小細胞肺癌之氧雜雙環庚烷
Hu et al. Current status of CPT and its analogues in the treatment of malignancies
KR20230038659A (ko) 나노 입자, 전리 방사선 및 그의 혁신적인 치료용 조합
Lu et al. Effects of paclitaxel liposome and capecitabine in the treatment of advanced gastric cancer by clinical observation
JP2021521130A (ja) 増殖性障害の治療のための投薬レジメン
Abdel-Ghany et al. Titanium oxide nanoparticles improve the chemotherapeutic action of erlotinib in liver cancer cells
Zia et al. Concurrent radiotherapy and chemotherapy with erlotinib followed by maintenance erlotinib in patients with Epidermal Growth Factor Receptor mutation-positive adenocarcinoma lung
Yingchun et al. Application of nano-drug delivery technology in overcoming drug resistance in lung cancer
AU2020356356A1 (en) Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
Park et al. Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer
Shin et al. Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma
Khan et al. MA01. 09 efficacy and safety of glembatumumab vedotin in patients with advanced or metastatic squamous cell carcinoma of the lung (PrECOG 0504)